Aspen APAC Divestment Unlocks R26.5 Billion For GLP-1 Focus

Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tagged APAC divestment, Aspen Pharmacare, BGH Capital, debt reduction, Eli Lilly, GLP-1 injectables, Healthcare Investment, mounjaro, shareholder vote, sterile manufacturing